Ribo Newsroom
-
Ribo Presents Kidney-Targeted Delivery Data at ASN Kidney Week 2025Ribo recently presented a poster at the ASN Kidney Week in Texas, showcasing the kidney-targeted delivery of siRNA using its RiboPepSTAR™ peptide conjugates.December 4, 2025 -
Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) InfectionRibo and Ribocure today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infection.October 24, 2025 -
Ribo Showcases New Clinical Data from Leading siRNA Programs at ESC 2025, Underscoring Significant Progress and Achievements in Advancing Cardiovascular TherapiesRibo and Ribocure Pharmaceuticals AB presented four key scientific findings at the 2025 European Society of Cardiology (ESC) Congress in Madrid, Spain, underscoring significant progress in siRNA-based cardiovascular therapeutics pipeline.September 10, 2025 -
Ribo Secures Series E Funding to Accelerate Global siRNA Therapeutics StrategyRibo secures series E funding to accelerate global siRNA therapeutics strategyJuly 21, 2025 -
Ribo's International R&D Center Ribocure Closes USD 33 Million Equity Financing to Accelerate Innovative siRNA Drug DevelopmentThe International R&D Center Ribocure closes USD 33 Million equity financing round.July 16, 2025 -
Ribo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in AustraliaRibo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in AustraliaFebruary 26, 2025